Product Images Donepezil Hydrochloride

This appears to be a table showing mean clinical improvement in ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) with three different treatments (Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and Placebo) over a period of weeks. However, the formatting and specific numbers are not fully clear, so the information is not completely reliable.*

This text seems to be presenting some type of graphical representation of data in regards to the effectiveness of a medication. The graph appears to show the cumulative percentage of patents experiencing change in ADAS-cog (a measurement tool for assessing cognitive performance in dementia patients) while being treated with Donepesil hydrochloride. The graph also shows the placebo group, suggesting that the medication is being compared to a placebo. Unfortunately, the information presented in this text is not sufficient to completely understand the purpose or results of this graph.*

This appears to be a chart or table displaying the percentage of patients who received either Donepezil hydrochloride 10mg/day, Donepezil hydrochloride 5mg/day, or a placebo, and how their condition improved or worsened according to the CIBIC-plus rating scale. The ratings range from "markedly improved" to "markedly worse."*

The text describes the change in ADAS-cog (Alzheimer's Disease Assessment Scale cognitive subscale) from baseline for three treatment options: Donepezil hydrochloride 10mg/day, Donepezil hydrochloride 5mg/day, and placebo over weeks of drug treatment. The mean improvement is represented as (+5E). The text suggests that both doses of Donepezil hydrochloride may provide clinical improvement.*

This text appears to be a table showing different dosages of Donepezil hydrochloride and placebo, along with the percentage of patients and their change in ADAS-cog scores. The table also mentions "Chsnne foms Buselin" at the end, but it is unclear what that refers to.*

This is a chart or table showing the percentages of patients who were given 10mg/day of Aricept, 5mg/day of Aricept, and a placebo, and how they were rated based on their improvement in the CIBIC-plus rating. The rating ranges from markedly improved to no change or worse.*

This is a clinical trial record indicating a comparison between donepezil hydrochloride 10mg/day and a placebo group. The changes from baseline are shown but it is difficult to determine the type of change being observed without additional context.*

This text seems to describe a medication called Donepezil HC 10mg, which is in the form of tablets with a lot number of 000000 and an NDC of 68071-1700-09. The medication is meant for prescription-use only and should be kept out of reach of children. The manufacturer's label should be checked for a full list of ingredients, and medical advice should be sought if any side effects occur. The medication should be stored at a controlled temperature between 59-86°F.*